HomeCompareYMTX vs NNN

YMTX vs NNN: Dividend Comparison 2026

YMTX yields 105.82% · NNN yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 YMTX wins by $4.91M in total portfolio value
10 years
YMTX
YMTX
● Live price
105.82%
Share price
$1.89
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.93M
Annual income
$1,723,843.10
Full YMTX calculator →
NNN
NNN REIT Inc.
● Live price
5.28%
Share price
$42.80
Annual div
$2.26
5Y div CAGR
2.8%
Payout ratio
71%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19.7K
Annual income
$1,147.75
Full NNN calculator →

Portfolio growth — YMTX vs NNN

📍 YMTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodYMTXNNN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, YMTX + NNN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
YMTX pays
NNN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

YMTX
Annual income on $10K today (after 15% tax)
$8,994.71/yr
After 10yr DRIP, annual income (after tax)
$1,465,266.64/yr
NNN
Annual income on $10K today (after 15% tax)
$448.83/yr
After 10yr DRIP, annual income (after tax)
$975.59/yr
At 15% tax rate, YMTX beats the other by $1,464,291.05/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of YMTX + NNN for your $10,000?

YMTX: 50%NNN: 50%
100% NNN50/50100% YMTX
Portfolio after 10yr
$2.47M
Annual income
$862,495.43/yr
Blended yield
34.86%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NNN right now

YMTX
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
-21.9
Piotroski
3/9
NNN
Analyst Ratings
10
Buy
15
Hold
4
Sell
Consensus: Hold
Price Target
$44.93
+5.0% upside vs current
Range: $43.00 — $48.50
Altman Z
1.1
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

YMTX buys
0
NNN buys
0
No recent congressional trades found for YMTX or NNN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricYMTXNNN
Forward yield105.82%5.28%
Annual dividend / share$2.00$2.26
Payout ratio50%71%
1-year div growth0%2.7%
5-year div CAGR0%2.8%
Portfolio after 10y$4.93M$19.7K
Annual income after 10y$1,723,843.10$1,147.75
Total dividends collected$4.43M$8.1K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: YMTX vs NNN ($10,000, DRIP)

YearYMTX PortfolioYMTX Income/yrNNN PortfolioNNN Income/yrGap
1← crossover$21,282$10,582.01$10,663$542.82+$10.6KYMTX
2$43,819$21,047.33$11,379$587.95+$32.4KYMTX
3$87,387$40,500.83$12,153$637.35+$75.2KYMTX
4$168,990$75,485.74$12,990$691.46+$156.0KYMTX
5$317,245$136,425.12$13,897$750.78+$303.3KYMTX
6$578,807$239,355.52$14,879$815.88+$563.9KYMTX
7$1,027,455$408,130.85$15,945$887.39+$1.01MYMTX
8$1,776,463$677,086.81$17,102$965.99+$1.76MYMTX
9$2,994,908$1,094,092.83$18,360$1,052.49+$2.98MYMTX
10$4,928,395$1,723,843.10$19,728$1,147.75+$4.91MYMTX

YMTX vs NNN: Complete Analysis 2026

YMTXStock

Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Full YMTX Calculator →

NNNREIT

NNN REIT (formerly National Retail Properties) is a Dividend King with 34+ consecutive years of dividend increases — one of only three REITs to achieve this status. Focuses on single-tenant properties with long-term net leases to operators in necessity-based retail sectors.

Full NNN Calculator →
📬

Get this YMTX vs NNN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

YMTX vs SCHDYMTX vs JEPIYMTX vs OYMTX vs KOYMTX vs MAINYMTX vs ADCYMTX vs EPRTYMTX vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.